Full-Time

Associate Director

Deadline 10/1/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

No salary listed

Barcelona, Spain

Hybrid

Three days on-site and two days working from home per week.

Bachelor's, Master's, PhD, Master of Arts (MA)

Category
Biology & Biotech (1)
Required Skills
Python
SAS
Data Science
R
Machine Learning
Electronic Health Records (EHR)
Biostatistics
Data Analysis

Get referred to Alexion

See people who can refer or advise you

Requirements
  • A Bachelor of Science, Master of Science, or Master of Arts degree in Statistics, Biostatistics, Computer Science, or Mathematics, or a PhD in a related area.
  • Expertise in statistical methodologies including general linear models, multivariate regression, nonparametric methods, and Bayesian inference.
  • At least 5 years of experience in data science or biostatistics and analytical programming using R, Python, SAS, and other languages in the biopharmaceutical or pharmaceutical industry.
  • Experience with big data science, machine learning, and artificial intelligence models.
  • Knowledge of clinical trials and experience analyzing and interpreting clinical trial data.
  • Strong written and oral communication skills.
  • Strong presentation and interpersonal skills.
  • Attention to detail while managing multiple projects under tight timelines.
  • Flexibility and adaptability to internal and external changes.
Responsibilities
  • Develop and implement the health economics and outcomes research analytics strategy, including conceptualizing real-world evidence studies, identifying data sources, conducting studies, and executing publication plans.
  • Perform hands-on programming in R, Python, SAS, and other programming languages or tools to work with real-world databases and identify target patient populations, treatment patterns, disease burden, healthcare resource utilization and costs, and other exploratory questions.
  • Design and implement health economics and outcomes research studies supporting clinical, economic, and patient-centered value propositions and reimbursement requirements.
  • Manage analytics consultants and oversee analysis activities by providing input to analysis plans, monitoring study conduct, and reviewing study results.
  • Provide statistical guidance and methodology and interpret analysis results.
  • Serve as a real-world data expert by identifying data sources and developing strategies to generate valid evidence from appropriate databases.
  • Provide disease-area insights to help shape clinical development strategies and generate real-world evidence for therapy value decisions.
  • Collaborate with the Biostatistics team on clinical trial post-hoc analyses.
  • Generate rapid real-world evidence to support development needs, accelerate clinical trial design, and facilitate timely decisions.
  • Support preparation of medical or payer advisory meetings to solicit feedback on products and therapeutic-area disease impacts.
  • Ensure quality and timely delivery of assigned studies and projects.
  • Support publication planning and execution and review and approve abstracts or manuscripts.
  • Participate in acquisition strategies for real-world data sources and additional analytical tools for analytic needs.
  • Contribute to the global health economics and outcomes research analytics infrastructure by developing best practices, identifying process-improvement areas, and providing measures to improve quality and efficiency.
Desired Qualifications
  • Understanding of the data structures and limitations of various real-world databases and experience working with large electronic medical record or claims databases.
  • Experience and knowledge in rare disease.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old